PNC-27 For Sale in 5mg vials for $150.00. It is a research peptide for education and development only. The research peptide PNC-27 is showing good results in killing cancer cells. More work is needed before it can be in mainstream medicine. Therefore, we are here to make sure researchers buy PNC-27 that is safe, and pure for study.
What is PNC-27?
The cancer peptide PNC-27 has the capability to join the cancer cells and kill them whilst not affecting any healthy human cells. PNC-27 is a non-toxic cancer-targeting peptide that specifically accumulates in cancer cells and targets them for killing via induction of a cell death pathway.
History of PNC-27
PNC-27 is the human form of a cancer-targeting peptide (CTP) that was originally derived from a sequence in the P53 gene. This peptide has good antitumor activity when studied in vitro and was shown to have significant antitumor activity in vivo using a mouse xenograft tumor model. It was shown to be non-toxic to the host animal, and not toxic to bone marrow stem cells.
PNC-27 For Sale for study only
The CTP has since been altered to include the H2 domain of the H-ficolin protein (a human protein). This altered peptide, “PNC-27”, has been shown to be an effective cancer treatment. It specifically targets cancer cells whilst not affecting normal human cells. PNC-27 has been shown to accumulate in the blood of cancer patients and kill tumor cells.
PNC-27 Mechanism of action
PNC-27 specifically targets cancer cells for killing via induction of a cell death pathway. PNC-27 enters the cancer cell and binds to an oncogene (or mutated gene) product to form a stable complex. When the CTP binds to the oncogene product, the complex can no longer transmit signals that turn on growth or inhibit the cell. This induces cell death.
Unlike other cancer therapies, which induce apoptosis and/or suppress growth, PNC-27 kills cancer cells by activating a pathway in the cancer cells that normally leads to death in these cells.
PNC-27 is not toxic to normal human cells. Therefore, the treatment should not affect blood cells, bone marrow, or any other healthy tissues.
Antitumor activity of PNC-27
PNC-27 has been shown to have antitumor activity in a xenograft mouse model. In vivo experiments also showed that PNC-27 accumulates in cancer cells, and PNC-27 is taken up by cancer cells in a dose-dependent manner. Once taken up by the cells, PNC-27 appears to be stable and does not diffuse out of the cells.
The peptide also showed activity in several other tumor models. In vivo experiments using human tumor cells showed that the peptide is highly effective in vivo and is capable of killing tumor cells in the blood. The treatment of mice with human tumor cells in the blood also showed that PNC-27 targets and kills human tumors. This means that the peptide is not only active in vivo, but it is also capable of killing human tumors.
In addition, PNC-27 has the capability to kill tumor cells that have been treated with a chemotherapeutic drug.